A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma

Conclusion.Sorafenib was poorly tolerated, and anti‐KS activity was modest. Strong CYP3A4 inhibitors may contribute to sorafenib toxicity, and ritonavir has previously been shown to be a CYP3A4 inhibitor. Alternate antiretroviral agents without predicted interactions should be used when possible for concurrent administration with sorafenib. The Oncologist 2017;22:505–e49

Source: The Oncologist - May 9, 2017 Category: Cancer & Oncology Authors: Thomas S. Uldrick, Priscila H. Goncalves, Kathleen M. Wyvill, Cody J. Peer, Wendy Bernstein, Karen Aleman, Mark N. Polizzotto, David Venzon, Seth M. Steinberg, Vickie Marshall, Denise Whitby, Richard F. Little, John J. Wright, Michelle A. Rudek, William D Tags: Chinese Edition, Clinical Trial Results Source Type: research